Recent years have seen a paradigm shift in the healthcare and biotechnology industries due to the introduction of cutting-edge technologies. Among these advancements is the emergence of multiplex assays, which have transformed how researchers approach diagnostic and research applications. By consolidating multiple assays into a single platform, researchers can streamline the analysis of complex biological samples, resulting in time and cost savings. According to Inkwood Research, the global multiplex assays market is expected to register a CAGR of 8.12% during 2024-2032 and reach a revenue of $7793.26 million by 2032.
Multiplex assays have been widely adopted across diverse fields, such as clinical diagnostics, drug discovery, genomics, and proteomics. This blog details the latest developments happening in the global multiplex assay market.
Request a FREE sample of the Multiplex Assay Market
Latest Developments in the Global Multiplex Assay Market
• Parhelia’s Omni-Stainer™: Enhanced and Automated Multiplex Assay
Understanding cellular function within a given microenvironment has become standard practice rather than an exception in life sciences research. The intricate relationships between cells and tissues dictate health outcomes, while molecular interactions within and among cells provide crucial context for understanding their collective effects.
Utilizing omics techniques to explore these relationships within native tissue environments offers spatial insight into cell heterogeneity and dynamics. This approach sheds light on disease progression, treatment responses, and genotype-phenotype correlations at both cellular and tissue levels. However, the accuracy of these maps depends on the quality of the underlying data.
Implementing automated sample preparation methods enhances data consistency, reproducibility, and throughput, particularly crucial for multiplex assays prone to manual variability and time constraints. Parhelia Biosciences envisioned an affordable solution to standardize multiplex assays, ensuring consistent and reproducible data across laboratories of all sizes.
The Parhelias’ Omni-Stainer™, a fully automated system, comprises a robotic chassis, thermal module, flow cells, software, and the company’s S12 staining module accommodating up to 12 slide-mounted samples. Staining employs capillary gap exchange, ensuring uniform coverage, minimal reagent waste, and simplified stain removal. Additionally, a dedicated thermal module sustains precise temperature control (0-99.9°C) for incubation.
Affordability was a key consideration in developing the Parhelia Omni-Stainer, as similar automated systems typically cost between $300,000 to $500,000, making them inaccessible to many laboratories. This drove the team to pursue an open-source approach during the development of CODEX (now PhenoCycler) at Stanford University’s Nolan Lab.
Explains Nikolay Samusik, Ph.D., co-founder and CEO of Parhelia, “Our experience demonstrated that accuracy in these assays doesn’t require paying too much for the fastest, shiniest system, which won’t automatically translate into solid data,” Samusik explains. “This drove our vision to own the spatial biology workflow by providing open-source solutions that enable labs of all sizes to streamline and standardize assay performance to ensure consistency and reproducibility.” (Source)
Get CUSTOMIZED market insights delivered right to your inbox!
• Enabling Comprehensive Quantification: Navigate BioPharma Services Inc’s Cutting-Edge Multiplex Digital PCR Assay
In the 2023 AAPS National Biotechnology Conference, Navigate BioPharma Services Inc, a subsidiary of Novartis known for its groundbreaking biomarker solutions in drug development, introduced its latest innovation: multiplex digital PCR assays. These assays provide a comprehensive means of quantifying multiple chimeric antigen receptor (CAR) T cells, a form of cancer immunotherapy that modifies T cells genetically to target and eliminate specific cancers. Leveraging the Qiagen QIAcuity digital PCR System, these assays offer a robust and user-friendly digital PCR experience facilitated by its innovative nanoplate system.
The innovative multiplex digital PCR assay facilitates simultaneous assessment of the quantity, activity, and persistence of CAR-T cells in clinical blood and bone marrow samples, eliminating the necessity for a standard curve. It boasts a sensitivity capable of detecting CAR-T cells as minute as 0.01% within normal T cell populations, delivering results in under two hours.
Further, this assay accommodates the measurement of up to five distinct CAR-T cell markers within a single reaction, utilizing specific probes tailored to different CAR targets, thus enabling the quantification of multiple CAR-domains or combinations of commonly utilized therapeutic targets in CAR-T therapies. Such capabilities empower clinicians to monitor response rates and safety profiles throughout clinical trials, facilitating the advancement of novel therapeutic approaches.
Says Dr. Nathan Riccitelli, Associate Director of Innovative Technologies at Navigate BioPharma Services Inc, “CAR-T therapy is a promising and innovative approach to treat cancer, but it requires accurate and reliable quantification of CAR-T cells for successful drug development. Our new proprietary multiplex digital PCR assay provides a comprehensive and robust solution for measuring CAR-T cells in clinical samples with high sensitivity, specificity and reproducibility.” (Source)
Stay up-to-date with what’s trending in the Global Multiplex Assay Market
Future Potential of Multiplex Assay Market
The development of multiplex tests enables the simultaneous measurement of multiple analytes in a single biological sample, minimizing assay time, cost, and sample volume. For instance, a multiplex test for respiratory viruses could deliver sensitive and accurate results right in the doctor’s office, facilitating immediate treatment initiation.
Furthermore, multiplex testing aids laboratories in conserving vital testing supplies such as pipettes, swabs, and reagents, all of which are in high demand. Additionally, it reduces reliance on single-use tests and enables labs to offer more comprehensive results in a shorter timeframe.
Moreover, studies have demonstrated that rapid multiplex testing reduces the length of stay (LOS) for ICU patients from 9.2 to 6.2 days (P < 0.0001). In a period marked by boarding and hospital overcrowding, a shorter LOS during ‘tripledemics’ enhances patient flow, thereby enhancing hospital productivity. Accordingly, the current and imminent global healthcare landscape offers lucrative growth opportunities for the global multiplex assay market.
Can’t find what you’re looking for? Talk to an expert NOW!
1. What are multiplex assays?
A: Multiplex assays are diagnostic tests that allow the simultaneous detection and measurement of multiple analytes in a single sample, streamlining the testing process and providing comprehensive results.
2. What are the benefits of using multiplex assays?
A: Using multiplex assays offers several advantages, including reduced assay time, cost-effectiveness, conservation of testing supplies, and the ability to provide comprehensive diagnostic information with minimal sample volume.
3. How are multiplex assays impacting the healthcare industry?
A: Multiplex assays are revolutionizing diagnostics in the healthcare industry by improving efficiency, accuracy, and turnaround time for testing. They play a crucial role in various applications, including disease diagnosis, drug discovery, biomarker analysis, and personalized medicine, driving advancements in patient care and treatment outcomes.
